Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
2mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Purity: ≥98%
Bimatoprost (AGN-192024; Latisse; Lumigan; Bimatoprostum; AGN192024) is a potent FP (Prostaglandin F) receptor agonist and a prostaglandin analog used topically as eye drops to control the progression of glaucoma and in the management of ocular hypertension. Bimatoprost has a mild aqueous humor flow stimulation rate of 14% at night and 13% during the day. Its ocular hypotensive action is primarily caused by a 26% reduction in tonographic resistance to outflow. Bimatoprost improves the outflow pathway that is sensitive to pressure. Bimatoprost, with a K(i) of 6.31 μM, displaces [3H]prostaglandin F(2alpha) from FP receptors. With EC(50) of 2.94 μM and 2.2 μM, bimatoprost rapidly mobilizes intracellular Ca(2+) via native FP receptors in 3T3 mouse fibroblasts and cloned human FP receptors expressed in human embryonic kidney cells.
ln Vitro |
|
||
---|---|---|---|
ln Vivo |
|
||
Animal Protocol |
|
||
References |
Molecular Formula |
C25H37NO4
|
|
---|---|---|
Molecular Weight |
415.57
|
|
Exact Mass |
415.27
|
|
Elemental Analysis |
C, 72.26; H, 8.97; N, 3.37; O, 15.40
|
|
CAS # |
155206-00-1
|
|
Related CAS # |
5,6-trans-Bimatoprost; 1163135-95-2; Bimatoprost-d5; Bimatoprost methyl ester; 38315-47-8; N-Desethyl Bimatoprost; 155205-89-3; Bimatoprost-d4
|
|
Appearance |
Solid powder
|
|
SMILES |
CCNC(=O)CCC/C=C\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/[C@H](CCC2=CC=CC=C2)O)O)O
|
|
InChi Key |
AQOKCDNYWBIDND-FTOWTWDKSA-N
|
|
InChi Code |
InChI=1S/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3-,17-16+/t20-,21+,22+,23-,24+/m0/s1
|
|
Chemical Name |
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.02 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.02 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.02 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.4063 mL | 12.0317 mL | 24.0633 mL | |
5 mM | 0.4813 mL | 2.4063 mL | 4.8127 mL | |
10 mM | 0.2406 mL | 1.2032 mL | 2.4063 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT03850782 | Active Recruiting |
Drug: Bimatoprost (SR) | Open-Angle Glaucoma Ocular Hypertension |
AbbVie | February 28, 2019 | Phase 3 |
NCT05397600 | Active Recruiting |
Drug: Bimatoprost Ophthalmic | Ocular Hypertension Glaucoma |
Laboratoires Thea | June 22, 2022 | Phase 3 |
NCT05335122 | Active Recruiting |
Drug: OTX-TIC low dose Travoprost Intracameral Implant Drug: OTX-TIC high dose Travoprost Intracameral Implant |
Open Angle Glaucoma Ocular Hypertension |
Ocular Therapeutix, Inc. | March 16, 2022 | Phase 2 |
NCT02390284 | Active Recruiting |
Drug: Latanoprost Drug: Bimatoprost Drug: Travoprost Drug: Timolol Drug: Dorzolamide |
Glaucoma | University of Miami | September 2015 | Phase 3 |
NCT06122090 | Recruiting | Drug: Bimatoprost Drug: Saline |
Burn Scar Scars Scarring Cicatrix Burns Laser |
Medstar Health Research Institute | July 18, 2023 | Phase 2 |
Regulation of Cyr61 and CTGF mRNA expression in cat iris following PGF2α, Butaprost, and Bimatoprost treatment. J Biol Chem . 2003 Jul 18;278(29):27267-77. td> |
Differential regulation of CTGF and Cyr61 following PGF2α, Bimatoprost, and Butaprost treatments. J Biol Chem . 2003 Jul 18;278(29):27267-77. td> |
Effects of PGF2α, Butaprost, and Bimatoprost (AGN 192024) on the CTGF promoter and Cyr61 promoter luciferase reporter activity. J Biol Chem . 2003 Jul 18;278(29):27267-77. td> |